Home infusion devices market projected to reach $17.83 billion by 2030

The home infusion therapy devices market is forecast to grow from $10.86 billion in 2025 to $17.83 billion by 2030, driven by chronic disease, aging populations, telehealth and a shift to home-based care. Asia-Pacific was the largest regional market in 2025 and is expected to grow fastest through 2030.

Why it matters: - Home infusion therapy devices are becoming central to the shift from hospital-based treatment to home-based care. - The market’s projected growth signals rising demand for controlled drug delivery, remote monitoring and long-term treatment outside clinical settings. - Faster adoption could affect patients who need antibiotics, nutrition support and ongoing medication at home.

What happened: - The Business Research Company projected the global home infusion therapy devices market will grow from $10.86 billion in 2025 to $12.03 billion in 2026. - The report forecasts the market will reach $17.83 billion by 2030. - The report puts the market on a 10.8% CAGR from 2025 to 2026 and a 10.3% CAGR through 2030. - Asia-Pacific was the largest regional market in 2025 and is expected to grow at the fastest pace through the forecast period.

The details: - Home infusion therapy devices deliver fluids, medications, nutrients and other therapeutic solutions directly into a patient’s body at home. - The devices are designed for controlled, accurate and safe therapy delivery. - The report ties near-term growth to chronic illness, demand for home healthcare, an aging population, higher hospital discharge rates and more long-term infusion treatments. - Longer-term growth is expected to come from expansion of home healthcare services, wider use of remote patient monitoring, preference for personalized drug delivery, higher healthcare spending and decentralized care models. - Emerging trends include portable infusion devices, ambulatory infusion pumps, disposable infusion equipment, home-based intravenous therapies and greater emphasis on precise drug delivery. - The market report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report edition adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis. - The company offers a free sample report at Download a free sample of the market report. - The full report is available at View the full market report.

Between the lines: - Telehealth and remote patient monitoring are making home infusion more practical because providers can track treatment progress and intervene sooner. - FAIR Health Inc. reported a 7.3% increase in national telehealth use in April 2023, with telehealth-related medical claim lines rising from 5.5% in December 2022 to 5.9% in January 2023. - The aging population is expanding the addressable base for home infusion, especially for patients who want more convenient and affordable care. - OECD data showed people age 65 and older made up 18.5% of the population across OECD countries by November 2025, with the group topping 252 million in 2023. - The growth story points to a broader move toward decentralized care, where devices, digital monitoring and patient convenience matter more.

What's next: - Adoption is likely to keep rising as healthcare systems expand home care programs and remote monitoring tools. - The report expects demand to strengthen as more patients and providers choose home-based infusion over repeated facility visits. - Asia-Pacific’s lead position suggests the fastest commercial momentum may continue in that region through 2030.

The bottom line: - Home infusion therapy devices are moving from a niche support tool to a core part of home-based healthcare, with double-digit growth expected through the end of the decade.